In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

The approval includes patients whose disease progressed after treatment with endocrine therapy, which can cause ESR1 mutations.

Patients on Enhertu and Perjeta lived more than three years without disease progression compared to just over two years on Perjeta, Herceptin, and chemo.

The firm has licensed Solid's AAV-SLB101 capsid and plans to fund preclinical development with a potential $1.1 million investment from the Jain Foundation.

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.

Recent studies are revealing how genetic counselors are adapting their practice amid state laws banning or restricting abortions.

The company submitted data showing A400's efficacy in patients with advanced RET fusion-positive NSCLC in first- or later-line treatment.

The firm's lead candidate, EN-374 for X-linked chronic granulomatous disease, is being evaluated in a Phase I/II trial.

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

The firm has randomized participants in the REGENERATE-PD study of AB-1005 in the UK and Poland, with plans to expand to Germany next.